Management of haemophilia patients in the COVID‐19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China

Objective To identify lessons learned from haemophilia care experience in Wuhan (COVID‐19 outbreak epicenter in China) and Tianjin (with relatively low COVID‐19 incidence) in the pandemic. Methods We compared the challenges in haemophilia management attributed to local COVID‐19 containment policies, healthcare resource availability, clotting factors supply, daily living restrictions and coping strategies employed. Results Wuhan was in lockdown with strict traffic controls, enforced quarantine and overwhelmed resources. Tianjin was in relatively relaxed countermeasures to COVID‐19. In Wuhan, haemophilia treatment (for bleeding, prophylaxis, multidisciplinary team care, immune tolerance induction) and patient education were severely affected, while the challenges in Tianjin were less. In both cities, patients’ fear for COVID‐19 infection also affected their management. Coping strategy in Wuhan included channelling of clotting factors supply from hospitals to nine pharmacies; timely transfers of in‐need patients to healthcare facilities by a volunteer service network jointly coordinated by the government, hospitals and the community. Although factor concentrate supply in each city was adequate, patients still worried whether there would be enough supply to last through the pandemics. Consequently, many downgraded their treatment regimens resulting in increased bleeding episodes. In both cities, telemedicine was promoted for patient care and education. Conclusions The COVID‐19 pandemic had varying adverse impacts on haemophilia care depending on the local infection incidence. Our experience suggests that haemophilia management strategies in the pandemic need to be established according to the local virus containment/mitigation policies, daily living restrictions and resource availability.